A Chinese biotech running after the “best-in-class” title in the PARP inhibitor field has gathered $30 million to fuel its still early-stage R&D work.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,